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e-mail address: gwynwilliams@doctors.org.uk (G.S. Williams).Gwyn Samuel Williams ⇑, Eulee Seow, Huw Evans, Muyiwa Owoniyi, Sam Evans, Christopher BlythAbstractAim: Providing intravitreal ranibizumab therapy for neovascular age related macular degeneration (nARMD) is a source of increas-
ing strain for many UK eye departments. Whilst most units attempt to adhere to the product licence of following up patients at four
weekly intervals; delays in follow up appointments can and do occur. We aim to see if mean follow up intervals during the main-
tenance phase are correlated with visual outcomes at one year and perform a multivariate analysis of patient factors in a bit to
understand the factors affecting visual acuity outcomes.
Method: A continuously updated prospective audit of patients receiving ranibizumab therapy at the Royal Gwent Hospital was
accessed and a coefficient of determination and Spearman’s rank test undertaken to see whether mean follow up delays resulted
in visual acuity penalties after nine months of maintenance. Multivariate analysis using ANOVA was then undertaken to examine in
more detail the various factors affecting visual acuity outcomes.
Results: 805 eyes of 708 patients were included in the study. Mean follow up intervals varied between 28.0 and 96.3 days over the
first six treatments of the maintenance phase (mean 49.2 – SD 10.7) with a mean change in visual acuity from baseline of +7.1
letters at 12 weeks and +4.6 letters at 52 weeks. There was a negative correlation seen between visual acuity gains after nine
months of the maintenance phase and increasing clinic follow up times although Spearman’s rank analysis demonstrated a
correlation coefficient of only 0.078, which was not statistically significant. Variability in follow up appointments resulting in worse
outcomes was however significant (p < 0.01), as was increasing age at presentation (p = 0.04). Smoking was found to decrease age
of presentation by six years (74.2 years vs 80.0 years). The adjusted R2 for the whole analysis was 0.44.
Conclusion: Wide variation in follow up intervals was associated with a worse visual acuity outcome although longer mean follow
up interval was not. Smokers presented at a significantly younger age than non-smokers or ex-smokers. This was a large study with
an adjusted R2 of 0.44. The results are relevant to other macular degeneration service providers around the world.
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It has been shown through multiple clinical trials that
inhibition of vascular endothelial growth factor (VEGF)
through intravitreal injection of 0.5 mg ranibizumab
(Lucentis, Novartis Pharma AG, Basel, Switzerland;
Genentech Inc, San Francisco, USA) is both safe and effectivein treating neovascular age related macular degeneration
(nARMD).1–4 The burden of visual loss caused by nARMD is
significant, as this condition alone is responsible for more
than half of all United Kingdom blind and partial sight
registrations in those over 50 years of age5 and carries a
marked adverse financial consequence for the economy
itself.6 Treating nARMD through the establishment ofe:
al.com
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drain of resources for the National Health Service (NHS),
necessitating the drafting of both Royal College of
Ophthalmologists and National Institute for Health and
Clinical Excellence (NICE) guidelines to operate anti-VEGF
delivery services as efficiently as cost effectively as
possible.7,8
The cornerstone of the United Kingdom NHS ranibizumab
intravitreal injection programme is based on the variable dos-
ing regimen outlined in the PrONTO Study, in which patients
receive three consecutive monthly injections followed by
retreatment dependent on certain criteria such as macular
thickness and visual acuity changes being met.9 This pro-
gramme of monthly surveillance with injection as required fol-
lowing the initial three loading injections was shown to be
non-inferior to continuous monthly injections as employed
in the earlier trials, although later research showed that com-
mencing the as-required programme from the very first injec-
tion did in fact result in poorer outcomes.10 Whilst some
studies have suggested that ranibizumab assessment and
delivery systems based on the PrONTO model do in fact have
poorer visual acuity and macular thickness outcomes at one
year compared to studies in which patients receive regular
monthly treatment regardless of disease activity11 still others
have published results outlining the safety and cost effective-
ness of extending clinic follow up appointments for selected
patients during the maintenance phase.12
In short, the very expensive monthly ranibizumab assess-
ment and delivery services that have been setup around the
United Kingdom to implement both NICE guidelines and
those of the Royal College of Ophthalmologists are based
upon the regime setup in some of the initial clinical trials
but the true effect of varying follow up periods for patients
in the first year of the maintenance phase is as yet unknown.
It is a possibility that extending the follow up period during
the maintenance phase has no effect on visual acuity and
other parameters after a period of one year, in which case
it might be argued that doing so would assist the planning
of anti-VEGF nARMD services and the allocation of resources
in an austere financial climate. On the other hand it might be
the case that extending appointment times may result in
poorer outcomes at one year and thus provide an evidence
based reason for improving funding for these services as
allowing follow up appointments to become delayed might
result in patient harm. This very interesting question has
not been previously addressed and we sought to do so using
the continuously updated prospective audit of patients that
has been ongoing at the Royal Gwent Hospital in Newport
since ranibizumab services were first commenced in 2007.
Since then, for various reasons, including resources, man
power and patient factors, mean follow up appointments
during the maintenance phase of ranibizumab therapy has
varied over the first year of maintenance from 28.0 to
96.3 days. Whilst exploring this issue we also set out to see
whether other factors such as the lesion type, age, and num-
ber of treatments given during the first year of treatment and
baseline visual acuity parameters also had any bearing on
visual acuity outcomes after nine months of maintenance.
The other two main factors explored were those of smoking
status and social deprivation.
Smoking is a known risk factor for nARMD13 and a putative
genetic link has been suggested for this14 the exact nature ofthe risk posed by smoking to visual acuity outcomes in NHS
macular clinics is not known and to date has not been
explored. Likewise whilst social deprivation has been shown
to be associated with poorer quality of life in the visually
impaired, the exact relationship between social deprivation
and visual acuity outcomes in the macular clinic has not been
previously explored.15
We report here on whether the variation in follow up,
smoking status, age, sex, baseline visual acuity, number of
treatments in the first nine months of the maintenance phase
and social deprivation has any bearing on visual acuity out-
comes at one year.Methods
Since the inception of the nARMD ranibizumab service at
the Royal Gwent Hospital in 2007 a continuously updated
prospective audit has been undertaken in order to assess
outcomes. We accessed this database in order to select the
patients who had been followed up for twelve or more
months at the unit who had been receiving ranibizumab injec-
tions for nARMD of all types. Those with alternate diagnoses
and those who had received prior photodynamic therapy
(PDT) were excluded from our analysis.
The eligible patient data were analysed for change in
visual acuity (in LogMAR letters) based on mean follow up
interval during the first nine months of the maintenance
phase and Spearman’s rank regression analysis undertaken
in order to determine the linear correlation between the
two variables. The first nine months of maintenance were
chosen specifically as the policy in our department is not to
vary appointment times based on patient response until the
second year of treatment, which would be a significant con-
founding factor. Classic and occult lesions were separated
from these data and analysed individually to see whether
they behaved differently from each other or from the group
as a whole.
Patients were asked about their smoking status (smoker,
ex-smoker or non-smoker) at initial presentation to the
nARMD service. Social deprivation was defined by the post-
code of their address, as the whole of Wales is divided into
1896 Lower Layer Super Output Areas (LLSOA) which are
ranked by the Welsh Government by their levels of depriva-
tion; the Welsh Index of Multiple Deprivation (WIMD), with
1 being the most deprived location and 1896 being the least.
Multivariate analysis in the form of ANOVA was under-
taken, using the ‘R’ statistical program, on all of the mea-
sured variables.Results
Analysis of the database revealed 805 eyes of 708 patients
that had been followed up at the Royal Gwent Hospital rani-
bizumab service with a diagnosis of nARMD for twelve
months or more, including nine months of maintenance ther-
apy, that had also not received prior PDT. Follow up during
the maintenance phase varied between 28.0 and 96.3 days
with a mean of 49.2 days, a median of 48.1 days and a stan-
dard deviation of 10.7 days. The change in visual acuity
(VA) for the group over nine months of maintenance therapy
was 2.3 letters with a standard deviation of 11.1 letters.
Factors affecting visual acuity after intravitreal ranibizumab 189Mean initial baseline LogMAR visual acuity in this group
was 0.64, with 21% of patients being >0.30 LogMAR. The
mean change in visual acuity from baseline was +7.1
LogMAR letters at 12 weeks (VA 0.50 and 38.0% >0.30)
and +4.6 letters at 52 weeks (VA 0.55 and 35.2% >0.30).
The mean number of ranibizumab treatments in the first year
was 5.9.
When change in visual acuity was plotted against follow up
interval during the maintenance period regression analysis
demonstrated a slope of -0.083 and a coefficient of
determination (R2) of 0.0063 (See Graph 1). Spearman’s rank
analysis of these data demonstrated a correlation coefficient
of 0.078 with a P value of >0.05.
Multivariate analysis of all the recorded variables was per-
formed using the Analysis of Variants (ANOVA) test with the
‘R’ statistical package. This demonstrated that increased age
at presentation, measured in years, was correlated with a
poorer outcome at -0.108 letters after nine months of main-
tenance (p = 0.04). If smokers (n = 171) and ex-smokers
(n = 206) were grouped together and compared with non-
smokers (n = 428) then although there was no statistically sig-
nificant difference in outcome at one year of follow up what
was striking was that the mean age of the smokers at
74.2 years old was significantly younger than those who had
never smoked, at 80.0 years. Better visual acuity at baseline
(0.082 letters at one year per extra letter seen initially,
p < 0.01) and greater improvement during the loading phase
(0.181 letters, p < 0.01) were both strongly associated with
poorer outcomes at one year, although this would be
expected as part of a ceiling effect.
Most interestingly, the mean follow up interval during
maintenance, the prime variable under investigation in thisGraph 1. The above graph demonstrates the large spread in visual acuity
independent of the mean follow up intervals. Classic membranes, represen
represented in green. The correlation between follow up interval and acuity o
form of neovascular membrane.study, was not associated with a statistically significant worse
outcome after nine months of maintenance (0.131 letters
per extra day delay in follow up, p = 0.08) although an
increased variability in follow up independent of mean delay
(0.389 letters, p < 0.01) was significant. Greater number of
ranibizumab treatments administered was associated with a
worse outcome (0.384 letters per extra treatment,
p = 0.05). Sex of the patient, membrane morphology and
social deprivation were not associated with any statistically
significant variation in visual acuity outcome. Altogether the
coefficient of determination (R2) for the whole study was
0.44.Discussion
The financial and structural implications of introducing
ranibizumab services for nARMD have been debated since
it was first introduced12,16. Since the first trials, most notably
MARINA3 and ANCHOR,2 first demonstrated considerable
visual acuity benefits to treating nARMD on a fixed monthly
regimen efforts have been made to see whether less intense
regimes can maintain the benefits whilst being overall more
cost-effective. As both of these studies demonstrated a ceil-
ing effect of ranibizumab efficacy after the first three injec-
tions the PIER study4 assessed whether reducing the
injection frequency to quarterly following the initial monthly
three loading dose injections was a non-inferior alternative.
Whilst the PIER study did indeed demonstrate poorer out-
comes compared with regular monthly injection subsequent
studies employing varying criteria to determine whether
retreatment was necessary; SAILOR17 and PrONTO9 espe-
cially, have now formed the basis of most ranibizumaboutcomes after treatment with ranibizumab and that these are largely
ted with red dots, are just as evenly distributed as occult membranes,
utcomes, represented by the slope, are surprisingly not significant for any
190 G.S. Williams et al.services offered in the United Kingdom National Health
Service for nARMD.
Whilst the evidence for the superiority of regular monthly
dosing was questioned by the CATT study18 efforts are con-
tinuing to try to find a more cost-effective way of managing
the huge workload that maintaining nARMD services has
become through treat and extend regimes.12 These have
been planned studies and to date no study has looked into
the implications of variable follow up appointments in
nARMD clinics during the maintenance phase in a real world
setting. Our study is the first to look at whether variations to
mean follow up appointment times during the maintenance
period of the first year of ranibizumab therapy, caused by
fluctuations in system capacity and delivery capabilities as
well as patient non-attendances, has a significant bearing
on visual acuity outcome.
The mean change in visual acuity from baseline in our
patients was +7.1 LogMAR letters at 12 weeks and +4.6 let-
ters at 52 weeks, significantly worse than similar published
figures in the main trials quoted above. It must be noted
however that 21% of our patients had visual acuities of
>0.30 at baseline, which is outside of the inclusion criteria
for most of the major studies, in line with evidence that rani-
bizumab therapy stabilizes good vision in these patients,19
which would obviously have a bearing on these results. Our
study also demonstrates the importance of this ceiling effect.
Patients entering the programme with good visual acuity or
performing very well during the induction phase had a sta-
tistically significant greater chance of reduced LogMAR visual
acuity during the maintenance phase.
The biggest surprise out of all the data was that variations
in mean follow up interval did not statistically significantly
affect visual acuity in the study. Whilst our data do suggest
a negative correlation between final visual acuity outcome
after nine months of maintenance therapy and an increasing
follow up interval, the regression analysis demonstrated a
slope of 0.083 and an R2 of 0.0063 with Spearman’s rank
analysis demonstrating a correlation coefficient of 0.078;
which indicates little linear correlation which was not sta-
tistically significant.
This set of results carries weight principally because it
includes results of patient episodes from routine NHS prac-
tice and reflects the reality of providing a government health
programme with service constraints and a significant delayed
attendance rate outside the controlled environment of a clini-
cal trial. It is possible that were certain groups isolated from
the cohort such as those not missing a single appointment or
others excluded such as those with catastrophic drops in
visual acuity for various reasons the result would fit a more
linear pattern. It might be argued that a further analysis of
the figures over a two or three year period of maintenance
rather than only nine months might form the basis of a more
robust relationship between mean follow up intervals and
visual acuity outcomes. Although there was a significant
spread the suggestion from our figures does suggest that if
this relationship continued or even increased over an
extended time period the results might become more signifi-
cant. It seems unlikely that this is possible using our data set
though as beyond nine months of maintenance clinical deci-
sion making comes into play and appointments are extended
purposefully; thus introducing a major confounding factor
beyond this point. What was highly significant however wasthe finding that increased variability in follow up appoint-
ments, as opposed to an increase in the mean, resulted in
worse outcomes (p < 0.01) and this might be important in
advising patients and those planning nARMD services of
the importance of reducing variation, perhaps at the cost of
an increase in the mean follow up interval. This is however
the first set of published figures to demonstrate this though
and further work here would be desirable before concrete
recommendations can be made.
The suggestion that smokers, whilst faring no worse after
a year of treatment compared to their ex-smoking or non-
smoking counterparts, present almost six years earlier is strik-
ing. We believe that this has not been demonstrated thus far
in a real-world health setting and might be important in
advising future smoking cessation campaigns.
The observation that patients undergoing increased num-
bers of treatments had statistically significantly worse results
(p = 0.05) may be because those with the most aggressive
disease would tend to require more injections of ranibizu-
mab, although interestingly there was no correlation
between membrane morphology and acuity outcomes. It is
also surprising perhaps that social deprivation did not have
any affect on visual acuity outcomes, although we are plan-
ning to examine this area in more detail in future studies.
Perhaps the most striking statistical finding is that of all the
data analysed in this large study the R2 was only 0.44, indicat-
ing that the parameters analysed only accounted for 44% of
the observed variation in acuity outcomes. It is notable that
this study did not include such ocular co-morbidities as the
presence of cataract, glaucoma or any systemic medical con-
dition that could affect sight and that the reason for appoint-
ment delay, being booking system or patient centred, was not
a part of the dataset. Patients who serially did not attend were
also included, provided they attended at least once more at
nine months from the completion of the loading phase.
Perhaps the best way of ascertaining whether an increase
in mean follow up interval truly did affect visual acuity out-
comes might be to set up a prospective study randomly
allocating patients to different fixed follow up schedules,
keeping note of all other ocular and systemic co-morbidities
from the beginning, following patients up for more than nine
months. The causes of variation in visual acuity outcomes
between different patients attending nARMD clinics though
does seem to be demonstrably more complex than perhaps
previously thought and ascertaining as many of these vari-
ables as possible to provide a tailored follow up service for
each patient might one day be the most effective solution
to the current stresses affecting macular services.Conflict of interest
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